Erythropoietin: a new perspective in cardiovascular therapy

Submitted: January 26, 2016
Accepted: January 26, 2016
Published: January 26, 2016
Abstract Views: 924
PDF: 1178
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Erythropoietin is a hormone produced by the kidney, which regulates proliferation, differentiation and maturation of red cells. Recombinant human EPO (rH-EPO) is well known to correct anaemia in patients with chronic renal failure in terminal stage. However, recent studies showed the existence of several not haematopoietic effects of erythropoietin. EPO receptors have been found to be expressed in several tissues, included the cardiovascular system. An increase in cardiac systolic function has been observed in patients with chronic heart failure treated with EPO. Other beneficial effects appear to be related to the pro-angiogenic properties on endothelial cells and could be useful for treatment of ischemic heart disease. These findings suggest that EPO could provide potential therapeutic benefits in the management of cardiovascular diseases beyond anaemia correction. This review focuses its attention on the pleiotropic effects of EPO and its future promising applications in cardiovascular pathology.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

How to Cite

Raddino, Riccardo, Debora Robba, Giorgio Caretta, Ivano Bonadei, Melissa Teli, Gregoriana Zanini, Alberto Madureri, Enrico Vizzardi, and Livio Dei Cas. 2016. “Erythropoietin: A New Perspective in Cardiovascular Therapy”. Monaldi Archives for Chest Disease 70 (4). https://doi.org/10.4081/monaldi.2008.414.